CME 16/06/16 – Anu’s Monthly EM Wrap 4
Here are the “hot off the press!” neurology studies that were presented by Anu at todays CME:
- Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage: Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-II) trial
- Designed to determine the efficacy of rapidly lowering the systolic blood-pressure level in patients in an earlier time window after symptom onset than that evaluated in previous trials (ie. INTERACT2) which showed a nonsignificantly lower rate of death and disability with target of <140mmHg vs <180mmHg.
- Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH Trial): a randomised, open-label, phase 3 trial
- Aimed to investigate whether platelet transfusion with standard care, compared with standard care alone, reduced death or dependence after intracerebral haemorrhage associated with antiplatelet therapy use.
- Here is the summary from Salim Rezaie at RebelEM.com: The PATCH Trial: Hold the Platelets in Spontaneous Intracerebral Hemorrhage?
- Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke (ENCHANTED Trial)
- To investigate whether thrombolytic therapy for acute ischaemic stroke with a lower-than-standard dose of intravenous alteplase may improve recovery along with a reduced risk of intracerebral hemorrhage.
- Here is the summary from Anand Swaminathan at RebelEM.com: The ENCHANTED Trial: Is Low-Dose the Right Dose for Intravenous tPA in Acute Ischemic Stroke?
